Examination of intralesional injections of IFNα-2a in the treatment of basal cell carcinoma has revealed that eleven lesions (55%) showed complete clinical and dermatopathological remission, six lesions (30%) were found to be in partial remission, two lesions (10%) exhibited no response with low recurrence rates in long-term follow-up and no serious adverse effects were observed [25]. This evidence concerns the gene IFNA2 and basal cell carcinoma.